Chemotherapy Combinations for Mantle Cell Lymphoma
Trial Summary
Will I have to stop taking my current medications?
The trial requires that patients switch from proton pump inhibitors to an alternative drug before starting acalabrutinib. Additionally, patients must not take strong or moderate CYP3A inhibitors or inducers within 7 days before the first dose of the study drug. If you are on these medications, you may need to stop or switch them.
What data supports the effectiveness of the drug combination for mantle cell lymphoma?
Research shows that combining rituximab, bendamustine, and cytarabine is effective for treating mantle cell lymphoma, with high response rates and prolonged survival in patients. Additionally, bendamustine and rituximab together have been shown to be effective with a favorable safety profile in treating this type of lymphoma.12345
Is the chemotherapy combination for mantle cell lymphoma safe for humans?
The combination of rituximab, bendamustine, and cytarabine has shown high activity but also high blood-related side effects in mantle cell lymphoma. Acalabrutinib, another drug in the combination, has been approved for mantle cell lymphoma and is considered to have minimal off-target effects, suggesting a favorable safety profile.12467
What makes the chemotherapy combination of Acalabrutinib, Bendamustine, Cytarabine, and Rituximab unique for treating mantle cell lymphoma?
This treatment is unique because it combines Acalabrutinib, a newer drug that targets specific proteins in cancer cells, with a regimen of Bendamustine, Cytarabine, and Rituximab, which have shown effectiveness in mantle cell lymphoma but can have high toxicity. The inclusion of Acalabrutinib may offer a novel approach to enhance treatment efficacy while potentially managing side effects.12489
What is the purpose of this trial?
This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to find out if one the drug combinations of bendamustine, rituximab, high dose cytarabine, and acalabrutinib is better or worse than the usual approach for mantle cell lymphoma.
Research Team
Nina D Wagner-Johnston
Principal Investigator
ECOG-ACRIN Cancer Research Group
Eligibility Criteria
This trial is for adults with newly diagnosed mantle cell lymphoma. Participants should be in good physical condition (ECOG score 0-2), have acceptable blood counts, liver and kidney function, and not be pregnant or breastfeeding. They must agree to use contraception and cannot have certain heart conditions, active infections, bleeding disorders, severe allergies to the drugs being tested, or be on specific medications that affect drug metabolism.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of three chemotherapy regimens: bendamustine, rituximab, and cytarabine; bendamustine, rituximab, cytarabine, and acalabrutinib; or bendamustine, rituximab, and acalabrutinib. Treatment cycles repeat every 28 days.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion. Follow-up occurs every 3 months for 3 years, then every 6 months until year 10.
Treatment Details
Interventions
- Acalabrutinib
- Bendamustine
- Cytarabine
- Rituximab
Acalabrutinib is already approved in United States, European Union for the following indications:
- Mantle cell lymphoma
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Mantle cell lymphoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
ECOG-ACRIN Cancer Research Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator